Download PDF
Dtsch Med Wochenschr 2003; 128(44): 2324-2328
DOI: 10.1055/s-2003-43189
Übersichten
Endokrinologie
© Georg Thieme Verlag Stuttgart · New York

Euthyreote Schilddrüsenknoten

Pathophysiologische Grundlagen der Prävention und medikamentösen Therapie[1] Pathophysiologic basis for prevention and pharmacotherapy of benign cold thyroid nodulesV. F. H. Brauer1 , R. Paschke1
  • 1Medizinische Klinik III, (Komm. Direktor: Prof. Dr. med. R. Paschke), Universität Leipzig
Further Information

Publication History

eingereicht: 20.2.2003

akzeptiert: 21.8.2003

Publication Date:
30 October 2003 (online)

Also available at
    Permissions and Reprints

Schilddrüsenknoten sind oftmals Zufallsbefunde und treten in milden Jodmangelgebieten Deutschlands bei 16-30 % der Erwachsenen, mit Bevorzugung des weiblichen Geschlechtes auf [23] [25] [28]. Sie stellen damit die häufigste endokrinologische Erkrankung dar [40]. Schilddrüsenknoten bergen die Risiken, maligne zu entarten oder Schilddrüsenfunktionsstörungen hervorzurufen. Diese Risiken sind von verschiedenen Faktoren, wie Umwelteinflüssen, Größe und Stoffwechselaktivität der Knoten, Alter und Geschlecht der Patienten abhängig. Deshalb müssen diese Einflüsse bei der Therapie von Knoten innerhalb und außerhalb von Studien Berücksichtigung finden. Die diagnostische Schwierigkeit liegt in der Unterscheidung zwischen benignen und malignen Läsionen.

Derzeit gibt es [im Gegensatz zu z. B. Nebenniereninzidentalomen, [26]] keine evidenzbasierten Richtlinien für den Umgang mit Schilddrüseninzidentalomen.

1 Der Beitrag „ Euthyreoter Schilddrüsenknoten: Therapieziele, Resultate und Perspektiven der medikamentösen Therapie” erscheint im nächsten Heft (Nr. 45).

Literatur

  • 1 Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.  J Intern Med. 2002;  251 407-414
    Google Scholar
  • 2 Baltisberger B L, Minder C E, Burgi H. Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency.  Eur J Endocrinol. 1995;  132 546-549
    Google Scholar
  • 3 Belfiore A, Garofalo M R, Giuffrida D. et al . Increased aggressiveness of thyroid cancer in patients with Graves’ disease.  J Clin Endocrinol Metab. 1990;  70 830-835
    Google Scholar
  • 4 Belfiore A, La Rosa G L, La Porta G A. et al . Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity.  Am J Med. 1992;  93 363-369
    Google Scholar
  • 5 Belfiore A, La Rosa G L, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area.  Cancer. 1987;  60 3096-3102
    Google Scholar
  • 6 Berghout A, Wiersinga W M, Smits N J, Touber J L. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter.  Am J Med. 1990;  89 602-608
    Google Scholar
  • 7 Brabant G, Bergmann P, Kirsch C M, Kohrle J, Hesch R D, von zur Muhlen A. Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man.  Metabolism. 1992;  41 1093-1096
    Google Scholar
  • 8 Bray G A. Increased sensitivity of the thyroid in iodine-depleted rats to the goitrogenic effects of thyrotropin.  J Clin Invest. 1968;  47 1640-1647
    Google Scholar
  • 9 Carrillo J F, Frias-Mendivil M, Ochoa-Carrillo F J, Ibarra M. Accuracy of fine-needle aspiration biopsy of the thyroid combined with an evaluation of clinical and radiologic factors.  Otolaryngol Head Neck Surg. 2000;  122 917-921
    Google Scholar
  • 10 Celani M F. Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter.  Exp Clin Endocrinol. 1993;  101 326-332
    Google Scholar
  • 11 Danese D, Sciacchitano S. The thyroid nodule. Diagnostic considerations.  Minerva Endocrinol. 1993;  18 129-137
    Google Scholar
  • 12 Daniels G H. Thyroid nodules and nodular thyroids: a clinical overview.  Compr Ther. 1996;  22 239-250
    Google Scholar
  • 13 Daumerie C, Ayoubi S, Rahier J, Buysschaert M, Squifflet J P. Prevalence of thyroid cancer in hot nodules.  Ann Chir. 1998;  52 444-448
    Google Scholar
  • 14 Dawson T, Wynford-Thomas D. Does autocrine growth factor secretion form part of a mechanism which paradoxically protects against tumour development?.  Br J Cancer. 1995;  71 1136-1141
    Google Scholar
  • 15 Dayan C M, Daniels G H. Chronic autoimmune thyroiditis.  N Engl J Med. 1996;  335 99-107
    Google Scholar
  • 16 Dugrillon A, Gartner R. delta-Iodolactones decrease epidermal growth factor-induced proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles-a possible mechanism of growth inhibition by iodide.  Eur J Endocrinol. 1995;  132 735-743
    Google Scholar
  • 17 Eggo M C, Sheppard M C. Autocrine growth factors produced in the thyroid.  Mol Cell Endocrinol. 1994;  100 97-102
    Google Scholar
  • 18 Filetti S, Bidart J M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.  Eur J Endocrinol. 1999;  141 443-457
    Google Scholar
  • 19 Führer D HH, Ruschenburg I, Paschke R. Diagnostik des Schilddrüsenknotens.  Dt Ärzteblatt. 2001;  38 2094-2100
    Google Scholar
  • 20 Gartner R, Dugrillon A, Bechtner G. Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid.  Acta Med Austriaca. 1996;  23 47-51
    Google Scholar
  • 21 Gharib H, James E M, Charboneau J W, Naessens J M, Offord K P, Gorman C A. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study.  N Engl J Med. 1987;  317 70-75
    Google Scholar
  • 22 Greer M A, Studer H, Kendall J W. Studies on the pathogenesis of colloid goiter.  Endocrinology. 1967;  81 623-632
    Google Scholar
  • 23 Gruning T, Zophel K, Wunderlich G, Franke W G. Prevalence of goiter and iodine deficiency in Saxony is less than previously assumed: A study 6 years after discontinuation of general iodization of table salt.  Med Klin. 2001;  96 1-8
    Google Scholar
  • 24 Grussendorf M. Therapy of euthyroid iron deficiency goiter. Effectiveness of a combination of L-thyroxine and 150 micrograms iodine in comparison with mono-L-thyroxine.  Med Klin. 1996;  91 489-493
    Google Scholar
  • 25 Hampel R, Kulberg T, Klein K. et al . Goiter incidence in Germany is greater than previously suspected.  Med Klin. 1995;  90 324-329
    Google Scholar
  • 26 Health. NIo .State of the science statement. Management of the clinically inapparent adrenal mass (incidentaloma). 2002
    Google Scholar
  • 27 Hicks D G, LiVolsi V A, Neidich J A, Puck J M, Kant J A. Clonal analysis of solitary follicular nodules in the thyroid.  Am J Pathol. 1990;  137 553-562
    Google Scholar
  • 28 Hoermann R, Quadbeck B. Course of thyroid nodules.  Exp Clin Endocrinol Diabetes. 1998;  106 S27-28
    Google Scholar
  • 29 Kahaly G, Dienes H P, Beyer J, Hommel G. Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter.  J Clin Endocrinol Metab. 1997;  82 4049-4053
    Google Scholar
  • 30 Klemenz B, Forster G, Wieler H. et al . Combination therapy of endemic goiter with two different thyroxine/iodine combinations.  Nuklearmedizin. 1998;  37 101-106
    Google Scholar
  • 31 Kopp P, Kimura E T, Aeschimann S. et al . Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters.  J Clin Endocrinol Metab. 1994;  79 134-139
    Google Scholar
  • 32 Krohn K, Fuhrer D, Holzapfel H P, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations.  J Clin Endocrinol Metab. 1998;  83 130-134
    Google Scholar
  • 33 Krohn K, Paschke R. Clinical review 133: Progress in understanding the etiology of thyroid autonomy.  J Clin Endocrinol Metab. 2001;  86 3336-3345
    Google Scholar
  • 34 Krohn K, Paschke R. Somatic mutations in thyroid nodular disease.  Mol Genet Metab. 2002;  75 202-208
    Google Scholar
  • 35 Krohn K, Reske A, Ackermann F, Muller A, Paschke R. Ras mutations are rare in solitary cold and toxic thyroid nodules.  Clin Endocrinol (Oxf). 2001;  55 241-248
    Google Scholar
  • 36 Kuma K, Matsuzuka F, Kobayashi A. et al . Outcome of long standing solitary thyroid nodules.  World J Surg. 1992;  16 583-587 , discussion 587-588.
    Google Scholar
  • 37 Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term follow-up.  World J Surg. 1994;  18 495-498
    Google Scholar
  • 38 La Rosa G L, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.  Ann Intern Med. 1995;  122 1-8
    Google Scholar
  • 39 Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies.  Am J Clin Pathol. 1988;  90 72-76
    Google Scholar
  • 40 Mazzaferri E L. Management of a solitary thyroid nodule.  N Engl J Med. 1993;  328 553-559
    Google Scholar
  • 41 Namba H, Matsuo K, Fagin J A. Clonal composition of benign and malignant human thyroid tumors.  J Clin Invest. 1990;  86 120-125
    Google Scholar
  • 42 Papini E, Guglielmi R, Bianchini A. et al . Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.  J Clin Endocrinol Metab. 2002;  87 1941-1946
    Google Scholar
  • 43 Papini E, Petrucci L, Guglielmi R. et al . Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.  J Clin Endocrinol Metab. 1998;  83 780-783
    Google Scholar
  • 44 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases.  N Engl J Med. 1997;  337 1675-1681
    Google Scholar
  • 45 Paschke R, Neumann S. Sodium/iodide symporter mRNA expression in cold thyroid nodules.  Exp Clin Endocrinol Diabetes. 2001;  109 45-46
    Google Scholar
  • 46 Pisarev M A, Kleiman de Pisarev D L. Biochemistry of thyroid regulation under normal and abnormal conditions.  J Endocrinol Invest. 1980;  3 317-329
    Google Scholar
  • 47 Reverter J L, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A. Suppressive therapy with levothyroxine for solitary thyroid nodules.  Clin Endocrinol (Oxf). 1992;  36 25-28
    Google Scholar
  • 48 Richter B, Neises G, Clar C. Pharmacotherapy for thyroid nodules. A systematic review and meta- analysis.  Endocrinol Metab Clin North Am. 2002;  31 699-722
    Google Scholar
  • 49 Rojeski M T, Gharib H. Nodular thyroid disease. Evaluation and management.  N Engl J Med. 1985;  313 428-436
    Google Scholar
  • 50 Russo D, Bulotta S, Bruno R. et al . Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter.  Eur J Endocrinol. 2001;  145 591-597
    Google Scholar
  • 51 Saller B, Hoermann R, Ritter M M, Morell R, Kreisig T, Mann K. Course of thyroid iodine concentration during treatment of endemic goitre with iodine and a combination of iodine and levothyroxine.  Acta Endocrinol (Copenh). 1991;  125 662-667
    Google Scholar
  • 52 Sawin C T, Geller A, Wolf P A. et al . Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Engl J Med. 1994;  331 1249-1252
    Google Scholar
  • 53 Schmutzler C, Kohrle J. Implications of the molecular characterization of the sodium-iodide symporter (NIS).  Exp Clin Endocrinol Diabetes. 1998;  106 S1-10
    Google Scholar
  • 54 Studer H GM. A study of the mechanisms involved in the production of iodine-deficient goiter.  Acta Endocrinol (Copenh). 1965;  49 610-628
    Google Scholar
  • 55 Terzioglu T, Tezelman S, Onaran Y, Tanakol R. Concurrent hyperthyroidism and thyroid carcinoma.  Br J Surg. 1993;  80 1301-1302
    Google Scholar
  • 56 Tonacchera M, Viacava P, Agretti P. et al . Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.  J Clin Endocrinol Metab. 2002;  87 352-357
    Google Scholar
  • 57 Tonacchera M, Vitti P, Agretti P. et al . Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.  J Clin Endocrinol Metab. 1999;  84 4155-4158
    Google Scholar
  • 58 Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.  J Clin Endocrinol Metab. 1996;  81 4278-4289
    Google Scholar
  • 59 Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases.  J Clin Endocrinol Metab. 1997;  82 1589-1593
    Google Scholar
  • 60 Wemeau J L, Caron P, Schvartz C. et al . Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo- controlled trial by the French Thyroid Research Group.  J Clin Endocrinol Metab. 2002;  87 4928-4934
    Google Scholar
  • 61 Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms.  Horm Res. 1997;  47 145-157
    Google Scholar
  • 62 Wynford-Thomas D, Stringer B M, Williams E D. Dissociation of growth and function in the rat thyroid during prolonged goitrogen administration.  Acta Endocrinol (Copenh). 1982;  101 210-216
    Google Scholar
  • 63 Yang G C, LiVolsi V A, Baloch Z W. Thyroid microcarcinoma: fine-needle aspiration diagnosis and histologic follow-up.  Int J Surg Pathol. 2002;  10 133-139
    Google Scholar
  • 64 Zelmanovitz F, Genro S, Gross J L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses.  J Clin Endocrinol Metab. 1998;  83 3881-3885
    Google Scholar

1 Der Beitrag „ Euthyreoter Schilddrüsenknoten: Therapieziele, Resultate und Perspektiven der medikamentösen Therapie” erscheint im nächsten Heft (Nr. 45).

Prof. Dr. med. Ralf Paschke

Komm. Direktor, Medizinische Klinik III, Universität Leipzig

Philipp Rosenthal-Straße 27

04103 Leipzig

Phone: 0341/9713200

Fax: 0341/9713209

Email: pasr@medizin.uni-leipzig.de

      >